TY - JOUR
AU - Solomonidou, Nantia
AU - Germanou, Daphnie
AU - Strouthos, Iosif
AU - Karagiannis, Efstratios
AU - Farolfi, Andrea
AU - Koerber, Stefan A
AU - Debus, Jürgen
AU - Peeken, Jan C
AU - Vogel, Marco E
AU - Vrachimis, Alexis
AU - Spohn, Simon K B
AU - Shelan, Mohamed
AU - Aebersold, Daniel
AU - Grosu, Anca-Ligia
AU - Ceci, Francesco
AU - Kroeze, Stephanie G C
AU - Guckenberger, Matthias
AU - Fanti, Stefano
AU - Belka, Claus
AU - Hruby, George
AU - Scharl, S.
AU - Wiegel, Thomas
AU - Bartenstein, Peter
AU - Henkenberens, Christoph
AU - Emmett, Louise
AU - Schmidt-Hegemann, Nina Sophie
AU - Ferentinos, Konstantinos
AU - Zamboglou, Constantinos
TI - PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA </td><td width="150">
TI - lt; 0.2 ng/ml.
JO - European journal of nuclear medicine and molecular imaging
VL - 50
IS - 8
SN - 1619-7070
CY - Heidelberg [u.a.]
PB - Springer-Verl.
M1 - DKFZ-2023-00497
SP - 2529-2536
PY - 2023
N1 - 2023 Jul;50(8):2529-2536
AB - The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml.The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed.The final cohort consisted of 273 patients; 78/273 (28.6
KW - PSMA-PET (Other)
KW - Prostate cancer (Other)
KW - Prostate-specific antigen (Other)
KW - Salvage radiotherapy (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:36905411
DO - DOI:10.1007/s00259-023-06185-5
UR - https://inrepo02.dkfz.de/record/274211
ER -